A cost-effectiveness analysis of Maraviroc in treatment-experienced HIV patients in Scotland
Journal of the International AIDS Society volume 11, Article number: P315 (2008)
Purpose of the study
The objective of this study was to perform a cost-effectiveness analysis of maraviroc therapy in patients with triple-class drug experience and/or triple-class drug resistance in Scotland, based on data from the MOTIVATE trials.
A Markov cohort model was developed in Excel based on the previously published ARAMIS model . Lifetime Maraviroc (MVC) treatment plus Optimized Background Therapy (OBT) was compared to standard OBT treatment in patients infected with CCR5-monotropic HIV-1. Disease states were defined according to CD4 cell counts and transition probabilities and drop-out rates were based on the MOTIVATE trials, complemented with data from the published literature. The model was populated with UK-specific costs (scaled to 2007 levels) and mortality rates for the Scottish general population. Efficacy was measured in quality-adjusted life-years (QALYs) and the analysis was performed from the perspective of the NHS. The base case input values and assumptions reflect a recent reimbursement submission.
Summary of results
MVC was associated with an incremental gain of 1.9 QALYs and incremental costs of £29,503 compared to standard OBT treatment, resulting in an incremental cost-effectiveness ratio (ICER) of £15,401 per QALY. Sensitivity analyses of input parameters and model assumptions produced ICERs in the range of £10,000–30,000.
The results indicated that it is potentially cost-effective to treat patients with MVC compared to standard OBT treatment in highly treatment-experienced HIV patients in Scotland.
Chancellor J, et al: A microsimulation of the cost-effectiveness of maraviroc for antiretroviral treatment-experienced HIV-infected individuals. ISPOR 13th Annual International Meeting. Toronto, Canada, 3–7. 2008, May : Presentation IN3
About this article
Cite this article
Lekander, I., Berg, J., Christie, A. et al. A cost-effectiveness analysis of Maraviroc in treatment-experienced HIV patients in Scotland. JIAS 11 (Suppl 1), P315 (2008). https://doi.org/10.1186/1758-2652-11-S1-P315
- Incremental Cost
- Drug Experience
- Cohort Model
- Incremental Gain